Epitan, Ltd.

Ethics approval obtained for PMLE trial in Melbourne

Published in Physician Law Weekly, October 12th, 2005

Epitan, Ltd., (EPT) announced that it has obtained ethics approval from the Human Research Ethics Committee of St. Vincent's Hospital, Melbourne, Australia, for a phase II trial of its melanin-producing drug EPT1647 as a treatment for polymorphous light eruption (PMLE), a common sun-related skin problem.

The principal investigator in the trial will be Dr. Chris Baker, director of clinical services, department of dermatology at St. Vincent's. The trial is scheduled to commence shortly.

Baker said: "Polymorphous light eruption is a common sun-induced skin disorder. The rash is intensely itchy and consists of obvious red patches and bumps. It occurs on...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2005-10-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry